Clinical trial • Phase I • Respiratory
GSK3862995B for Chronic obstructive pulmonary disease
Phase I trial of GSK3862995B for Chronic obstructive pulmonary disease. 55 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Chronic obstructive pulmonary disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 04-10-2024
- First CTIS Authorization Date
- 22-01-2025
Trial design
Phase I trial across 16 sites in Germany.
- Target Sample Size
- 55
Eligibility
Recruits 55 No vulnerable population selected (isVulnerablePopulationSelected=false).
- Vulnerable Population
- No vulnerable population selected (isVulnerablePopulationSelected=false)
Recruitment
- Planned Sample Size
- 55
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 16
- Total Number Of Participants
- 55
Germany
- Earliest CTIS Part Ii Submission Date
- 14-01-2025
- Latest Decision Or Authorization Date
- 03-11-2025
- Processing Time Days
- 293
- Number Of Sites
- 16
- Number Of Participants
- 55
Sites
- Site Name
- Klinische Forschung Karlsruhe GmbH
- Contact Person Name
- Frank Zollmann
- Contact Person Email
- frank.zollmann@pratia.com
- Site Name
- Lungenfachklinik Immenhausen
- Contact Person Name
- Peter Hammerl
- Contact Person Email
- hammerl@lungenfachklinik-immenhausen.de
- Site Name
- Velocity Clinical Research Germany GmbH
- Contact Person Name
- Nakul Modi
- Contact Person Email
- nmodi@velocityclinical.com
- Site Name
- Klinische Forschung Schwerin GmbH
- Contact Person Name
- Charlotte von Engelhardt
- Contact Person Email
- charlotte.engelhardt@pratia.com
- Site Name
- Klinische Forschung Dresden GmbH
- Contact Person Name
- Peter Heymer
- Contact Person Email
- peter.heymer@pratia.com
- Site Name
- Salvus-Klinische Studien GmbH
- Contact Person Name
- Regina Deckelmann
- Contact Person Email
- studien@dr-deckelmann.de
- Site Name
- Klinische Forschung Hamburg GmbH
- Contact Person Name
- Michael Froer
- Contact Person Email
- michael.froer@pratia.com
- Site Name
- Klinische Forschung Berlin-Mitte GmbH
- Contact Person Name
- Hans Peter Gmuender
- Contact Person Email
- hans.peter.gmuender@pratia.com
- Site Name
- Klinische Forschung Hannover-Mitte GmbH
- Contact Person Name
- Jan Wagner
- Contact Person Email
- jan.wagner@pratia.com
- Site Name
- Pneumologisches Studienzentrum München-West, Gemeinschaftspraxis fuer Lungen- und Bronchialheilkunde
- Contact Person Name
- Rainald Fischer
- Contact Person Email
- rainald.fischer@gmail.com
- Site Name
- Hamburger Institut fuer Therapieforschung GmbH
- Department Name
- Pneumologicum
- Contact Person Name
- Hartmut Timmermann
- Contact Person Email
- timmermann@pneumologicumhh.de
- Site Name
- Velocity Clinical Research Germany GmbH
- Contact Person Name
- Henrik Watz
- Contact Person Email
- hwatz@velocityclinical.com
- Site Name
- IKF Pneumologie GmbH & Co. KG
- Contact Person Name
- Stephanie Korn
- Contact Person Email
- korn@ikf-pneumologie.de
- Site Name
- IKF Pneumologie GmbH & Co. KG
- Contact Person Name
- Marc Oliver Kornmann
- Contact Person Email
- kornmann@ikf-pneumologie.de
- Site Name
- Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR
- Contact Person Name
- Lennart Schaper
- Contact Person Email
- lennart.schaper@studienpraxis-bb.de
- Site Name
- PAREXEL International GmbH
- Contact Person Name
- Simone Flöttmann
- Contact Person Email
- simone.floettmann@parexel.com
Sponsor
Primary sponsor
- Full Name
- Glaxosmithkline Research & Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- GSK3862995B
Related trials
Other published trials that may interest you.
- AZITHROMYCIN DIHYDRATE for Chronic obstructive pulmonary disease
- DEPEMOKIMAB for Chronic obstructive pulmonary disease
- Clinical trial in Chronic Obstructive Pulmonary Disease
- 6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE for Chronic obstructive pulmonary disease
- DUPILUMAB for Chronic obstructive pulmonary disease